Vir Biotechnology (VIR)
(Real Time Quote from BATS)
$10.20 USD
+0.17 (1.70%)
Updated Jul 22, 2024 03:18 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
VIR 10.20 +0.17(1.70%)
Will VIR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VIR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VIR
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates
Vir Biotechnology (VIR) Up on Positive Data From HDV Study
VIR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Vir Biotechnology (VIR) Could Surge 188.65%: Read This Before Placing a Bet
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates
GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance
Other News for VIR
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
Vir gets FDA clearance, fast track designation for tobevibart and elebsiran
Vir Biotechnology: A Cautious Hold Amid Promising Prospects and Key Data Anticipation